Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 19, 2020 08:00 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics Receives FDA Rare Pediatric Disease Designation for OV101 for the Treatment of Angelman Syndrome

NEW YORK, June 19, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare...
June 11, 2020 08:00 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics Announces Strategic Research Collaboration Focused on Accelerating the Development of New Treatments for Rare Neurological Diseases

Broad multiyear alliance with Columbia University Irving Medical Center researchers to focus on development of potential medicines using genetic based therapies and create a therapeutic platform for a...
June 08, 2020 08:00 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics Announces Multiple Presentations on the 2020 American Academy of Neurology Science Highlights Platform

NEW YORK, June 08, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare...
June 04, 2020 08:00 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics Launches Pipeline Teach-In Webinar Series

Company to host first webinar on Wednesday, June 17, to review OV935 (soticlestat) development program for rare developmental and epileptic encephalopathies (DEE) NEW YORK, June 04, 2020 (GLOBE...
May 12, 2020 08:00 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics Announces Participation in the 2020 RBC Capital Markets Virtual Global Healthcare Conference

NEW YORK, May 12, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare...
May 07, 2020 08:00 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update

Announced earlier today positive topline results from the Phase 2 ROCKET trial of OV101 for the treatment of Fragile X syndromePreviously reported encouraging initial results from Phase 2 ARCADE study...
May 07, 2020 07:30 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics Announces Positive Topline Results from the Phase 2 ROCKET Trial of OV101 for the Treatment of Fragile X Syndrome

OV101 met the study’s primary objective of safety and tolerabilityOV101 produced statistically significant reductions in behavioral and functional symptoms in individuals with Fragile X...
March 30, 2020 08:00 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics Announces Initial Data with Soticlestat in CDKL5 Deficiency Disorder and Dup15q Syndrome

Soticlestat continues to appear to be safe and well-tolerated; the majority of the 11 patients showed a reduction in seizures All patients that have completed the Phase 2 ARCADE study to date have...
March 11, 2020 08:00 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results, Provides Corporate Update for 2020

Multiple clinical data readouts across Ovid’s pipeline expected in 2020Completed financings in the fourth quarter strengthening the balance sheet NEW YORK, March 11, 2020 (GLOBE NEWSWIRE) -- Ovid...
March 05, 2020 16:05 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics Announces Multiple Presentations at the American Academy of Neurology 2020 Annual Meeting

NEW YORK, March 05, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare...